Heartbeam Inc. Common Stock (BEAT)
Stock · NASDAQ · Health Care
$0.436as of 10/16/2026
Price chart
BEAT Signal Track Record
How signals performed across all stocks →What BEAT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | -5.2% | 45% | October 1, 2026 |
| Bollinger Band Breakout | 22 | -1.6% | 50% | October 5, 2026 |
| Bollinger Band Breakdown | 18 | -4.7% | 33% | September 25, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +3.9% | 50% | November 4, 2025 |
| Any 20-session window (baseline) | -5.8% | 39% |
Computed by MarketWall from daily closing prices since August 29, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BEAT
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart's electrical signals from three dimensions for high-fidelity data collection and advanced diagnost…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 16
- Website
- www.heartbeam.com/
Fundamentals
- 1-day range
- $0.471$0.5099
- Market cap
- $28.33M
- P/E (trailing)
- —
- P/E (forward)
- -0.91
- EPS (trailing)
- $-0.51
- Dividend yield
- —
- Beta
- -0.83
- Avg. volume
- 7.39M
Forecasts
2 analyst ratings
Heartbeam Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BEATHeartbeam Inc. Common Stock$0.436▲ 0.93%Market cap $28.33MP/E —$0.355$4
- CNSYCerenome Inc. Common Stock$1.7▼ 9.57%Market cap $26.57MP/E —$1.49$4.16
- CTSOCytosorbents Corporation Common Stock$4.11▲ 34.31%Market cap $25.05MP/E —$2.96$18.8
- ARAYAccuray Incorporated Common Stock$0.16▼ 5.88%Market cap $33.63MP/E —$0.1615$1.86
- NSPRInspireMD Inc. Common Stock$0.46▼ 4.17%Market cap $33.87MP/E —$0.4604$2.54
- PLRZPolyrizon Ltd. Ordinary Shares$10▼ 0.10%Market cap $21.51MP/E —$2.88$18.2
- PAVMPAVmed Inc. Common Stock$2.41▼ 0.62%Market cap $35.93MP/E —$2.27$28.44
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BEAT Heartbeam Inc. Common Stock | $28.33M | — | $0.436 | ▲ 0.93% | $0.355$4 |
| CNSY Cerenome Inc. Common Stock | $26.57M | — | $1.7 | ▼ 9.57% | $1.49$4.16 |
| CTSO Cytosorbents Corporation Common Stock | $25.05M | — | $4.11 | ▲ 34.31% | $2.96$18.8 |
| ARAY Accuray Incorporated Common Stock | $33.63M | — | $0.16 | ▼ 5.88% | $0.1615$1.86 |
| NSPR InspireMD Inc. Common Stock | $33.87M | — | $0.46 | ▼ 4.17% | $0.4604$2.54 |
| PLRZ Polyrizon Ltd. Ordinary Shares | $21.51M | — | $10 | ▼ 0.10% | $2.88$18.2 |
| PAVM PAVmed Inc. Common Stock | $35.93M | — | $2.41 | ▼ 0.62% | $2.27$28.44 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- These stocks have an unusual volume in today's sessionChartMill · 10/6/2026
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga · 10/6/2026
- Monday's session: top gainers and losersChartMill · 10/5/2026
- Which stocks are most active on Monday?ChartMill · 10/5/2026
- Keep an eye on the top gainers and losers in Monday's session.ChartMill · 10/5/2026
- HeartBeam stock soars on FDA breakthrough designationYahoo · 10/5/2026
- BC-Most Active StocksYahoo · 10/5/2026
- Monday's session: gap up and gap down stocksChartMill · 10/5/2026
Insider Activity
Insider Actions →- Elfrink Willem · October 2, 2026 · Grant93.8K
- JAFF MICHAEL R · October 2, 2026 · Grant37.5K
- JAFF MICHAEL R · October 2, 2026 · Grant93.8K
- Nelson Kenneth Warwick III · October 2, 2026 · Grant31.3K
- Nelson Kenneth Warwick III · October 2, 2026 · Grant93.8K
- Ortigas-Wedekind Marga · October 2, 2026 · Grant81.3K
- Ortigas-Wedekind Marga · October 2, 2026 · Grant93.8K
- de Urioste George · October 2, 2026 · Grant93.8K
- Richard Ferrari · October 2, 2026 · Grant125.0K
- Richard Ferrari · October 2, 2026 · Grant90.6K
- Persen Kenneth Harry · July 24, 2026 · Grant105.7K
- Cruickshank Tim · July 24, 2026 · Grant167.8K
- Vajdic Branislav · July 24, 2026 · Grant260.9K
- Vajdic Branislav · June 15, 2026 · Grant2.80M
- Richard Ferrari · April 16, 2026 · Buy57.5K @ $0.8
Institutional Ownership
March 31, 2026
- Total shares held
- 4.98M
- Total value held
- $6.08M
- Institutional holders
- 35
- Unknown1.20M
- Unknown898.3K
- Unknown377.2K
- Unknown367.6K
- Unknown335.2K
- Unknown247.5K
- Unknown208.2K
- Unknown208.2K
- Unknown173.9K
- Unknown132.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
HeartBeam Receives FDA Breakthrough Designation for Heart Attack Test
HeartBeam Inc. announced that its Home Heart Attack Test system has been granted FDA Breakthrough Device designation. The designation recognizes the product’s potential to improve early detection of heart attacks at home. The company’s technology could expand its market presence and support future regulatory approvals. The news adds to the company’s positive momentum amid a mixed market session.
HeartBeam Receives FDA Breakthrough Designation for Heart Attack Test. HeartBeam Inc. announced that its Home Heart Attack Test system has been granted FDA Breakthrough Device designation. The designation recognizes the product’s potential to improve early detection of heart attacks at home. The company’s technology could expand its market presence and support future regulatory approvals. The news adds to the company’s positive momentum amid a mixed market session.